Eurosoft Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 1.20 M
- Company Age 29 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 144.06%
- Profit Growth 154.25%
- Ebitda 70.39%
- Net Worth 35.55%
- Total Assets 34.33%
About Eurosoft Pharma
Eurosoft Pharma Private Limited (EPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 April 1995 and has a history of 29 years and nine months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.20 M, as per Ministry of Corporate Affairs (MCA) records.
Nilesh Doshi, Paresh Chandrakant, Rikin Nilesh, and One other member serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230MH1995PTC087378
-
Company No.
087378
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Apr 1995
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Eurosoft Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nilesh Doshi
|
Director | 09-Nov-2021 | Current |
|
Paresh Chandrakant
|
Director | 18-May-1995 | Current |
|
Rikin Nilesh
|
Director | 31-Jul-2013 | Current |
|
Rupal Jhaveri
|
Director | 04-Mar-2022 | Current |
Financial Performance of Eurosoft Pharma.
Eurosoft Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 144.06% increase. The company also saw a substantial improvement in profitability, with a 154.25% increase in profit. The company's net worth Soared by an impressive increase of 35.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eurosoft Pharma?
In 2023, Eurosoft Pharma had a public holding of 20.15%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Qualichem Specialties Private LimitedNilesh Doshi is a mutual person
-
Riki International Private Limited
Nilesh Doshi and Rikin Nilesh are mutual person
-
Paras Krupa Paradise Private Limited
Rupal Jhaveri is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Eurosoft Pharma?
Unlock and access historical data on people associated with Eurosoft Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eurosoft Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eurosoft Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
